UroGen Pharma (URGN) announced that adult patients living with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer now have improved access to an important therapy, as the ...
Senate majority leader Bill Frist's surprise call for a two-year ad moratorium for newly approved prescription drugs greatly heightens pressure on the pharmaceutical industry to alter ...
BCD Meetings & Incentives last week launched an EMEA-wide Pharmaceutical Code Compliance Team to reassure clients it operates within the strict requirements governing meetings staged by pharmaceutical ...